Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Chronetics Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the management's prepared remarks, we will hold a question and answer session. Please press star followed by one on your telephone keypad. If you change your mind, please press star followed by two. I would now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss the first quarter 2025 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer, Dr. Dana Pizzuti, Chief Medical and Development Officer, Isabel Calafonos, Chief Commercial Officer, and Toby Schilke, Chief Financial Officer. Dr. Alan Krasner, Chief Endocrinologist, will also be joining for the Q&A portion. Please note there is a slide deck for today's presentation, which is in the events and presentation section of the investors page on the Crunetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we will be making forward looking statements and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filing. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release. The company's other news releases and chronetics SEC filings, includ...